Exploring Platform Versatility
CVBio has the potential to advance additional pipeline candidates leveraging its versatile platform technology.
By encoding powerful immune modulators, such as T-cell agonists, Treg antagonists, and checkpoint inhibitors, in its virus-driven platform, the company can develop therapeutic armed viruses.
The first candidates, expressing members of the tumor necrosis factor receptor superfamily that enhance T-cell activity, show remarkable efficacy in animal models of cancer, including breast, skin, brain, and lung.
CVBio is continuing to expand its pipeline with additional potent molecules and approaches to treat cancers that are resistant to currently available therapies.